Abstract
Immunotherapy has already become another option in the treatment of lung cancer. Nivolumab (Opdivo) is a fully humanized IgG4 monoclonal antibody against PD-1, which was first approved by the FDA and EMA initially for the treatment of advanced squamous and later nonsquamous NSCLC progressing after treatment with a platinum doublet without testing PD-L1.
The ap-proval was based on the results of phase III studies CheckMate 017 and CheckMate 057.